(VIANEWS) – NAVAMEDIC (NAVA.OL), LERØY SEAFOOD GP (LSG.OL), VISTIN PHARMA (VISTN.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.15.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 28. Meaning, the purchaser of the share is investing kr28 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
More news about NAVAMEDIC.
2. LERØY SEAFOOD GP (LSG.OL)
12.1% sales growth and 3.73% return on equity
Lerøy Seafood Group ASA produces, processes, markets, sells, and distributes seafood products worldwide. It operates in three segments: Wildcatch; Farming; and Value-Added Processing, Sales and Distribution. The company offers smoked and gravad salmon, and trout products; farmed and wild catch whole fishes; fillets and portions; ready-to-eat and ready-to-cook products; fish blocks and cubes; breaded products; pre-fried fish burgers and patties; crustaceans and molluscs; seaweeds; and other products. Lerøy Seafood Group ASA markets its products primarily under the Norway Seafoods, Arctic Supreme, Fjord trout, Aurora Salmon, Fossen, Sea Eagle, Lerøy, and M?r brands to shops, restaurants, canteens, and hotels. The company was founded in 1899 and is headquartered in Bergen, Norway. Lerøy Seafood Group ASA is a subsidiary of Austevoll Seafood ASA.
Earnings Per Share
As for profitability, LERØY SEAFOOD GP has a trailing twelve months EPS of kr1.02.
PE Ratio
LERØY SEAFOOD GP has a trailing twelve months price to earnings ratio of 43.25. Meaning, the purchaser of the share is investing kr43.25 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.73%.
More news about LERØY SEAFOOD GP.
3. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 5.32% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.34.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 68.53. Meaning, the purchaser of the share is investing kr68.53 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VISTIN PHARMA’s EBITDA is 2.36.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr23.30 at 07:20 EST, under its 52-week high of kr25.10 and way above its 52-week low of kr11.25.
More news about VISTIN PHARMA.
